Heterotopic Ossification: Molecular Drivers, Subtype-Specific Mechanisms, and Translational Therapeutic Advances
Biomolecules · 15.04.2026 · 16 (4) · 585
DOI: 10.3390/biom16040585 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 15.04.2026. Verfasst von Sihong Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China. Hauptthemen laut MEDLINE: Ossification, Heterotopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 282 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Heterotopic ossification (HO), the pathological formation of mature bone in non-skeletal soft tissues (e.g., muscles, tendons), severely impairs patient mobility and quality of life. Despite decades of research, systematic analysis of signaling networks across HO subtypes (acquired traumatic HO, hereditary Fibrodysplasia Ossificans Progressiva (FOP), Progressive Osseous Heteroplasia (POH)) remains insufficient, and clinical therapies suffer from high recurrence and severe side effects. This review synthesizes recent advances in HO pathogenesis: FOP involves gain-of-function activin A receptor type I (ACVR1) mutations (mostly R206H), disrupting bone morphogenetic protein (BMP)/Activin A signaling; POH arises from paternal guanine nucleotide-binding protein, alpha-stimulating activity polypeptide (GNAS) loss-of-function mutations, derepressing Hedgehog signaling via reduced cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) activity; tHO features trauma-induced inflammation/hypoxia activating BMP/transforming growth factor–beta (TGF-β) pathways. Key signaling crosstalk (e.g., BMP-Yes-associated protein (YAP)-Indian hedgehog (IHH)) is integrated, and novel therapies (ACVR1 inhibitors, Activin A antibodies, retinoic acid receptor gamma (RARγ) agonists, adeno-associated virus (AAV)-mediated ACVR1 silencing) are highlighted, with emphasis on subtype-specific efficacy. A stratified, mechanism-based HO management framework is proposed, aiming to accelerate precision therapy development and advance understanding of aberrant tissue regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
- Queen Mary School, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
ORCID-Profile: Sihong Chen, Hui Lin
Zitieren
APA
Chen, S., & Lin, H. (2026). Heterotopic Ossification: Molecular Drivers, Subtype-Specific Mechanisms, and Translational Therapeutic Advances. Biomolecules, 16(4), 585. https://doi.org/10.3390/biom16040585
Vancouver
Chen S, Lin H. Heterotopic Ossification: Molecular Drivers, Subtype-Specific Mechanisms, and Translational Therapeutic Advances. Biomolecules. 2026;16(4):585. doi:10.3390/biom16040585
BibTeX
@article{Chen2026,
author = {Chen, Sihong and Lin, Hui},
title = {Heterotopic Ossification: Molecular Drivers, Subtype-Specific Mechanisms, and Translational Therapeutic Advances},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {4},
pages = {585},
doi = {10.3390/biom16040585}
}
EUVIMED